Patents by Inventor Celine Bonnefous

Celine Bonnefous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090105124
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of TGR5 activity in a human or animal subject are also provided for the treatment diseases mediated by TGR5.
    Type: Application
    Filed: August 18, 2008
    Publication date: April 23, 2009
    Applicant: Kalypsys, Inc.
    Inventors: Nicholas D. Smith, Joseph E. Payne, Timothy Z. Hoffman, Celine Bonnefous, Anothony B. Pinkerton, Dana L. Siegel
  • Publication number: 20080312286
    Abstract: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: July 26, 2005
    Publication date: December 18, 2008
    Inventors: Anthony B. Pinkerton, Jean-Michel Vernier, Rowena Cube, John Hutchinson, Celine Bonnefous, Theodore Kamenecka
  • Publication number: 20080293684
    Abstract: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: July 26, 2005
    Publication date: November 27, 2008
    Inventors: Anthony B Pinkerton, Jean-Michel Vernier, Rowena V. Cube, John H. Hutchinson, Dehua Huang, Celine Bonnefous, Steven P. Govak, Theodore Kamenecka
  • Publication number: 20080194681
    Abstract: Disclosed herein are carbonyl compounds of Formula: (I) as described herein. Compounds as modulators of his-tone deacetylase (HDAC), pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
    Type: Application
    Filed: December 9, 2005
    Publication date: August 14, 2008
    Applicant: Kalypsys, Inc.
    Inventors: James Malecha, Stewart Noble, Christian Hassig, Paul Wash, Brandon Wiley, Charles Lawrence, Timothy Hoffman, Celine Bonnefous, NIcholas Smith
  • Patent number: 7408067
    Abstract: Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: August 5, 2008
    Assignee: Merck + Co., Inc.
    Inventors: Peter Charles Astles, Stephen Richard Baker, Celine Bonnefous, Jean Michel Vernier, Martine Keenan, Adam Jan Sanderson
  • Publication number: 20080139558
    Abstract: The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.
    Type: Application
    Filed: February 23, 2007
    Publication date: June 12, 2008
    Applicant: KALYPSYS, INC.
    Inventors: Nicholas D. Smith, Jeffrey R. Roppe, Celine Bonnefous, Joseph E. Payne, Hui Zhuang, Xiaohong Chen, Andrew K. Lindstrom, Sergio G. Duron, Christian A. Hassig, Stewart A. Noble
  • Publication number: 20070149547
    Abstract: The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel amides and/or compositions containing these compounds.
    Type: Application
    Filed: February 9, 2005
    Publication date: June 28, 2007
    Inventors: Celine Bonnefous, Theodore Kamenecka, Jean-Michel Vernier
  • Publication number: 20070135431
    Abstract: Disclosed herein are carbonyl compounds of having the structural formula: or a salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
    Type: Application
    Filed: December 8, 2006
    Publication date: June 14, 2007
    Applicant: KALYPSYS, INC
    Inventors: Nicholas Smith, Celine Bonnefous, Joseph Payne, Timothy Hoffman, Paul Wash, Christian Hassig, Shawn Scranton
  • Publication number: 20070060618
    Abstract: The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled compounds. In particular, the present invention is directed to 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled heterocyclic alkynes and methods of their preparation. The present invention further includes a method of use of the 11C, 18F, 15O, or 13N labeled heterocyclic alkyne compounds as tracers in positron emission tomography (PET) imaging, particularly in the study of metabolic conditions in mammals, specifically conditions modulated by metabotropic glutamate receptors subtype 5 (mGluR5).
    Type: Application
    Filed: October 24, 2003
    Publication date: March 15, 2007
    Applicant: MERCK & CO., INC.
    Inventors: Nicholas David Cosford, Steven Govck, Terence Hamill, Theodore Kamenecka, Thomas Seiders, Jeffrey Roppe, Celine Bonnefous, Donald Burns, Matthew Braun, Dennis Dean, Joseph Simeone
  • Publication number: 20070027184
    Abstract: Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
    Type: Application
    Filed: July 27, 2006
    Publication date: February 1, 2007
    Inventors: James Malecha, Stewart Noble, Brandon Wiley, Timothy Hoffman, Celine Bonnefous, Michael Sertic, Paul Wash, Nicholas Smith, Christian Hassig, Shawn Scranton, Joseph Payne, Jeffery Hager
  • Publication number: 20070027321
    Abstract: The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.
    Type: Application
    Filed: August 27, 2004
    Publication date: February 1, 2007
    Inventors: Theodore Kamenecka, Jean-Michel Vernier, Celine Bonnefous, Steven Govek, John Hutchinson
  • Patent number: 7087601
    Abstract: Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: August 8, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Jeannie Arruda, Celine Bonnefous, Brian T. Campbell, Rowena V. Cube, Benito Munoz, Brian Stearns, Jean-Michel Vernier, Bowei Wang, Xiumin Zhao
  • Publication number: 20060069088
    Abstract: Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.
    Type: Application
    Filed: May 13, 2005
    Publication date: March 30, 2006
    Inventors: Stephen Goble, Sander Mills, Lihu Yang, Alexander Pasternak, Celine Bonnefous, Theodore Kamenecka, Jean-Michel Vernier, John Hutchinson, Essa Hu, Steven Govek
  • Publication number: 20050070520
    Abstract: Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Application
    Filed: July 29, 2002
    Publication date: March 31, 2005
    Inventors: Peter Astles, Stephen Baker, Celine Bonnefous, Jean Vernier, Martine Keenan, Adam Sanderson
  • Publication number: 20050065340
    Abstract: Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at 2 the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
    Type: Application
    Filed: November 26, 2002
    Publication date: March 24, 2005
    Inventors: Jeannie Arruda, Celine Bonnefous, Brian Campbell, Rowena Cube, Benito Munoz, Brian Stearns, Jean-Michel Vernier, Bowei Wang, Xiumin Zhao